Abstract
Background Cerebral hyperperfusion syndrome (CHS) is not a common but severe complication after carotid artery stenting (CAS). We investigated whether prophylactic low-dose dexmedetomidine, a selective α2-adrenoceptor agonist, can decrease cerebral hyperperfusion induced brain injury after carotid artery stenting.
Methods This randomised, double-blind, placebo-controlled trial was conducted in a tertiary-care hospital in Zhengzhou, China. Patients aged 18 to 80 years old who had undergone CAS and from whom written informed consent was obtained, were enrolled between Jul 20, 2019 and Oct 10, 2022. Patients were randomly assigned to receive either intravenous dexmedetomidine (0·1 μg/kg/h, from insertion of the laryngeal mask until 72hr on postoperative day 3) (n = 80) or placebo (intravenous normal saline) (n = 80). The primary endpoint was the incidence of cerebral hyperperfusion (CH) and cerebral hyperperfusion syndrome (CHS), which were assessed six times with Transcranial Doppler sonography (TCD) during the postoperative three days. This study was registered with the Chinese Clinical Trial Registry, www.chictr.org.cn, ChiCTR1900024416.
Results CH occurred in 30 (37·5%) of 80 patients given a placebo and in 9 (11·2%) of 80 patients given dexmedetomidine (odds ratio [OR] 0·211, 95% CI 0·09-0·48; p<0·001). Further, CHS was significantly lower in the Dex group than in the placebo group (2.5% vs 13·75%; [OR] 0·16, 95% CI 0·03-0·71; p=0·017). Correspondingly, dexmedetomidine significantly upregulated serum brain-derived neurotrophic factor (BDNF) and downregulated neuronal injury biomarker neurofilament light chain (Nfl). The hierarchical clustering analysis revealed little difference in lipids metabolites between the two groups pre- and post-operatively, with Dex treatment uniquely increased lysphosphatidylethanolamine (LPE).
Conclusions A low prophylactic dose of dexmedetomidine significantly decreased the occurrence of cerebral hyperperfusion and cerebral hyperperfusion syndrome during the first three days after carotid artery stenting surgery.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
ChiCTR1900024416
Funding Statement
National Natural Science Foundation of China (No. 82271288) and Henan Provincial Science and Technology Research Project (No. 202102310124)
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Ethics Committee of People's Hospital of Zhengzhou University (2019-43), China
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Will individual participant data be available (including data dictionaries)? Yes What data in particular will be shared? All of the individual participant data collected during the trial, after de-identification. What other documents will be available? Study protocol, statistical analysis plan, Informed consent form, clinical study report, analytic code When will data be available (start and end dates)? Following, publication With whom? Anyone who wishes to access the data For what types of analyses? Any purpose By what mechanism will data be made available? Data are available indefinitely at link to be included
